EQT Life Sciences Invests in Exciva's Alzheimer's Research
EQT Life Sciences has recently announced its significant investment aimed at advancing clinical trials for innovative Alzheimer's treatments, focusing on addressing agitation associated with Alzheimer's disease (AD). The funding round, totaling EUR 51 million, has been co-led by EQT Life Sciences through its LSP Dementia Fund along with Gimv. Other participants in this round include Fountain Healthcare Partners, LifeArc, Carma Fund, and Modi Ventures, as well as returning investors like Andera Partners and LBBW.
Understanding the Importance of the Investment
This latest financing effort is crucial for supporting Exciva's Phase 2 clinical trial of its lead candidate, Deraphan. This candidate aims to tackle agitation—a common and distressing symptom experienced by many patients with severe AD. Neuropsychiatric symptoms, including agitation, impact up to 90% of these patients, contributing to caregiver stress and decreasing their quality of life. Despite the growing need for effective treatments, options remain limited.
Exciva's Plan and Innovative Approach
Exciva is set to launch its Phase 2 clinical trial across multiple regions, including the EU, United States, and Canada. The objective is to evaluate Deraphan, a unique combination of two established compounds, one of which is a new chemical entity engineered to treat the symptoms of AD effectively. Previous Phase 1 trials have indicated encouraging safety and tolerability outcomes, showing that Deraphan may usher in an advantageous alternative compared to current treatment protocols.
Exciva's Leadership Weighs In
François Conquet, the CEO of Exciva, expressed optimism regarding the funding, stating, "We are delighted that we could attract funding from both new and existing investors, supporting our belief that our compound is promising. If the results of the Phase 2 trials are positive, it would be a significant milestone in symptomatic treatment options for patients with AD." This conveys not only confidence in their product but reinforces Exciva's commitment to addressing a substantial unmet need within Alzheimer’s care.
Expert Insights from EQT Life Sciences
Philip Scheltens, MD, PhD, Partner at EQT Life Sciences, reaffirmed the investment’s significance, highlighting the potential of Exciva to spearhead therapeutic innovation amid a pressing need for effective Alzheimer's treatments. He noted, "This investment illustrates the potential of Exciva to bring exciting innovation to a therapeutic area where Alzheimer's patients have limited or no treatment options. We are delighted to co-lead this financing to help realize Exciva's potential, which stands out for both the quality of its science and the expertise of its team. We look forward to bringing this innovation to patients."
The Path Ahead for EQT Life Sciences and Exciva
As a result of this strategic investment, EQT Life Sciences will have representation on Exciva's board with Philip Scheltens appointed as a Director and Juliette Lee serving as an Observer. This representation further emphasizes EQT's dedication to monitoring and contributing to the future success of Exciva's initiatives.
The funding comes at a pivotal time when Alzheimer's care is at the forefront of public health discussions, especially given the increasing global aging population. With this investment, Exciva may well lead the charge in developing effective treatments, establishing a pathway to improved quality of life for countless individuals affected by Alzheimer's disease.
EQT Life Sciences continues to demonstrate its commitment to high-impact neuroscience therapeutics, paving the way for advancements in treating Alzheimer's and other neurodegenerative diseases. By backing innovative companies like Exciva, EQT reinforces its role as a key player in the life sciences investment arena, focusing on solutions that can transform patient care.
Frequently Asked Questions
What is Exciva's lead candidate for Alzheimer's treatment?
Exciva's lead candidate is Deraphan, designed to address agitation associated with Alzheimer's disease.
Who co-led the funding for Exciva?
The funding round for Exciva was co-led by EQT Life Sciences and Gimv, along with contributions from several other venture capital firms.
How does agitation affect Alzheimer's patients?
Agitation can severely impact the quality of life for up to 90% of Alzheimer's patients, creating stress for caregivers and leading to increased healthcare utilization.
What regions will the Phase 2 clinical trial cover?
The Phase 2 clinical trial for Exciva's Deraphan will take place across the EU, United States, and Canada.
What position will EQT representatives hold on Exciva's Board?
Philip Scheltens will serve as a Director, while Juliette Lee will act as an Observer on Exciva's Board following the investment.
